Koo Dicken D H, Roberts Ian S D, Quiroga Isabel, Procter Jeanette, Barnardo Martin C N M, Sutton Margaret, Cerundolo Lucia, Davies David R, Friend Peter J, Morris Peter J, Fuggle Susan V
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Transplantation. 2004 Aug 15;78(3):398-403. doi: 10.1097/01.tp.0000128328.68106.54.
Deposition of the complement protein C4d in renal allograft biopsies obtained during graft dysfunction and rejection has been proposed to be a sensitive marker of antibody-mediated acute rejection. To determine the diagnostic specificity of C4d deposition, it is important to study biopsies from allografts with no evidence of dysfunction. In this study, we examined C4d deposition in protocol biopsies obtained irrespective of clinical status.
Immunohistochemistry for C4d was performed on routine protocol biopsies preimplantation and on day 7 posttransplantation from 48 unselected renal allografts. Serum samples obtained up to 1 month after transplantation were assayed for donor-reactive antibodies (DRA). Results were correlated with histopathology and clinical outcome measures.
Diffuse C4d deposition was detected in the peritubular capillaries of 6 of 48 (13%) biopsies. C4d deposition was present in 5 of 15 (33%) biopsies that showed acute rejection (Banff 97, category 4) but only in 1 of 33 (3%) biopsies with no rejection (P=0.003, 97% specificity). Posttransplant DRAs were detected in 21 of 48 (44%) patients. All five recipients with C4d deposition and rejection had posttransplant DRA; the recipient whose biopsy showed C4d positivity, but not rejection, did not have detectable DRA. C4d deposition was not treated with plasmapheresis or intravenous immunoglobulin and was not associated with poor posttransplant graft outcome at 1-year follow-up.
Our results show that in early posttransplant protocol biopsies, C4d is a specific marker for the presence of humoral rejection, as indicated by its association with DRA and acute histologic rejection.
在移植肾功能障碍和排斥反应期间获取的肾移植活检组织中,补体蛋白C4d的沉积被认为是抗体介导的急性排斥反应的敏感标志物。为了确定C4d沉积的诊断特异性,研究没有功能障碍证据的同种异体移植活检组织很重要。在本研究中,我们检查了与临床状态无关的方案活检组织中的C4d沉积情况。
对48例未经选择的肾移植受者移植前和移植后第7天的常规方案活检组织进行C4d免疫组织化学检测。检测移植后1个月内获取的血清样本中的供体反应性抗体(DRA)。结果与组织病理学和临床结局指标相关。
在48例活检组织中的6例(13%)的肾小管周围毛细血管中检测到弥漫性C4d沉积。在显示急性排斥反应(Banff 97,4级)的15例活检组织中的5例(33%)中存在C4d沉积,但在无排斥反应的33例活检组织中仅1例(3%)存在C4d沉积(P=0.003,特异性97%)。48例患者中有21例(44%)检测到移植后DRA。所有5例C4d沉积且发生排斥反应的受者均有移植后DRA;活检显示C4d阳性但未发生排斥反应的受者未检测到DRA。C4d沉积未进行血浆置换或静脉注射免疫球蛋白治疗,在1年随访时与移植后移植物不良结局无关。
我们的结果表明,在移植后早期方案活检中,C4d是体液排斥反应存在的特异性标志物。这表现为它与DRA和急性组织学排斥反应相关。